ALXO ALX Oncology Holdings Inc.: Enterprise Value-to-Revenue Multiple

Public company logo of ALX Oncology Holdings Inc. (ALXO)

High dependence on a single CD47 blocking method creates significant risks for ALX Oncology Holdings (ALXO). This EV/Sales chart helps identify areas of market overvaluation for the asset, where 0.00 serves as the base parameter value. US-based research and a next-generation platform support the business's stability. A competitive advantage is provided by the drug evorpacept, which effectively destroys tumors while preserving erythrocytes.

Company Value to Revenue: ALX Oncology Holdings Inc. (ALXO) for 11/23/2025 - 11/21/2026

alxoncology.com - analytical breakdowns and key metrics (ALXO)

- share price and consensus valuation forecast:
Initial company analysis:ALX Oncology Holdings ALXO
Product sample of ALX Oncology Holdings

This multiple compares the total enterprise value of ALX Oncology Holdings (ALXO) with its annual revenue, excluding the impact of leverage to determine the actual market value of the assets. By analyzing the EV/Sales valuation ratio, an investor determines the extent of priced-in expectations regarding the success of CD47 immunotherapy, where a high valuation reflects the potential for breakthrough clinical trials by ALX Oncology Holdings (ALXO) in the fight against cancer.

Competitor analysis for ALX Oncology Holdings

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue XNCR|compasstherapeutics.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Replimune Inc.|Lyell Immunopharma (LYEL) - Enterprise Value-to-Revenue Ratio|Innate Pharma S.A. - Business Value to Revenue|PYXS (Pyxis) - EV/Sales Multiple|EV/Sales Multiple cgen.com|Enterprise Value-to-Revenue Ratio IO Biotech (IOBT)|STRO: Enterprise Value to Sales Volume|MiNK Therapeutics Inc. - Company Value to Revenue|werewolftx.com (HOWL) - Enterprise Value-to-Revenue Multiple|Immix Biopharma Inc. - EV/Sales Multiple|CUE - EV/Sales Multiple|PDSB: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - EV/Sales Multiple|Company Value to Revenue Liminatus Pharma (LIMN)|EV/Sales Multiple LVTX|Enterprise Value-to-Revenue Coefficient NXTC|Leap Therapeutics, Inc. - Company Value to Revenue|INTS: Company Value to Revenue Ratio|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP